2027 ICD-10-CM Diagnosis Code D47.9Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified
ICD-10-CM Codes›C00–D49›D37-D48›D47
- Billable — Valid for Submission
- CC — Complication or Comorbidity
- Risk Adjusts — HCC 21
- Not Chronic
D47.9 is a billable ICD-10-CM diagnosis code for neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 820 through 825, 840 through 842. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 133 closely related codes. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Neoplasms of unspecified nature or uncertain behavior.
For Medicare Advantage risk adjustment, D47.9 maps to CMS-HCC Category 21 (Lymphoma and Other Cancers) under the V28 model, adding a risk factor of about 0.671 for a community, non-dual, aged beneficiary in payment year 2027.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
D47.9 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.
Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Acquired angioedema due to lymphoproliferative disorder
- Acquired C1 esterase inhibitor deficiency
- Angioedema due to disorder of kinin metabolism
- Atypical lymphoproliferative disorder
- Autosomal recessive lymphoproliferative disease
- Chronic lymphoproliferative disorder of natural killer cells
- Disease caused by Human herpesvirus 8
- Drug-induced immunodeficiency
- Germinotropic lymphoproliferative disorder caused by Human herpesvirus 8
- Hematologic neoplasm of uncertain behavior
- Iatrogenic immunodeficiency-associated lymphoproliferative disorder
- Lymphoid neoplasm
- Lymphoproliferative disorder
- Lymphoproliferative disorder caused by methotrexate
- Myeloid neoplasm associated with beta-type platelet-derived growth factor receptor gene rearrangement
- Neoplasm of hematopoietic cell type
- Plasma cell neoplasm
- Progressively transformed germinal centers
- Secondary autoimmune hemolytic anemia due to lymphoproliferative disorder
- Systemic Epstein-Barr virus positive T-cell lymphoproliferative disease of childhood
- Vasculitis due to lymphoproliferative disorder
- Virus-associated atypical lymphoproliferative disorder
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to D47.9: its own notes plus those printed at block D37-D48 and Chapter 2. A note printed at a category, block or chapter applies to every code under it.
Applicable To
Conditions this code is used for: synonyms of the title or, for "other specified" codes, the conditions assigned to it. The list is not exhaustive.
- Lymphoproliferative disease NOS
Excludes1
Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.
- neoplasms of unspecified behavior (D49.-)
Notes
General instructions on how these codes are used.
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
Disease, diseased See Also: Syndrome;
lymphoproliferative D47.9
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Hematopoietic and Lymphoid System Neoplasm
a benign or malignant (primary or metastatic) neoplasm that affects the hematopoietic and lymphatic system.
Table of NeoplasmsClinical
Anatomical sites in the Table of Neoplasms that reference this code family.
Patient EducationClinical
Blood Disorders
Your blood is living tissue made up of liquid and solids. The liquid part, called plasma, is made of water, salts and protein. Over half of your blood is plasma. The solid part of your blood contains red blood cells, white blood cells and platelets.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert D47.9 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About D47.9Overview
Is D47.9 a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What MS-DRG does D47.9 group to?
When neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified is the principal diagnosis on an inpatient stay, it groups to MS-DRG 841, 821, 822, 825, 842, 824, 840, 820, 823, with relative weights from 0.9948 to 6.2454 depending on complications. Higher weights mean higher Medicare reimbursement.
Is D47.9 a CC or MCC?
CMS lists D47.9 as a CC (complication or comorbidity) for FY 2027. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 133 closely related codes in its exclusion list.
Can D47.9 be reported with a code from D49?
Not as a rule. The Excludes1 note at block D37-D48, which applies to D47.9, lists "neoplasms of unspecified behavior (D49.-)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).
What is the ICD-9 equivalent of D47.9?
Under the General Equivalence Mappings, neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified converts to ICD-9-CM 238.79 (lymph/hematpoitc tis NEC). The mapping is approximate, so confirm the match fits the documentation.
What HCC is D47.9?
D47.9 (neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified) maps to CMS-HCC Category 21 (Lymphoma and Other Cancers), commonly written as HCC 21, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 48 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 21.
Does D47.9 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, D47.9 adds a risk adjustment factor of about 0.671 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.493 to 0.739 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, and HCC 20) supersedes it when both are reported. See the full factor table on the HCC 21 category page.
